{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:37:26Z","timestamp":1793356646106,"version":"4.5.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40263-026-01290-z","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:57:14Z","timestamp":1775674634000},"page":"865-881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3926-747X","authenticated-orcid":false,"given":"Yong Moon","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-4408","authenticated-orcid":false,"given":"H. Steve","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-3722","authenticated-orcid":false,"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-8973","authenticated-orcid":false,"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"12","key":"1290_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40263-024-01130-y","volume":"38","author":"P Klein","year":"2024","unstructured":"Klein P, Friedman D, Kwan P. Recent advances in pharmacologic treatments of drug-resistant epilepsy: breakthrough in sight. CNS Drugs. 2024;38(12):949\u201360.","journal-title":"CNS Drugs"},{"issue":"10","key":"1290_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/14656566.2025.2517352","volume":"26","author":"SM Melnick","year":"2025","unstructured":"Melnick SM, Misra SN, Kamin M, Ferrari L, Glenn KJ. Potential of cenobamate as a broad-spectrum antiseizure medication. Expert Opin Pharmacother. 2025;26(10):1177\u201389.","journal-title":"Expert Opin Pharmacother"},{"key":"1290_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38\u201348.","journal-title":"Lancet Neurol"},{"issue":"22","key":"1290_CR4","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322.","journal-title":"Neurology"},{"issue":"10","key":"1290_CR5","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","volume":"99","author":"P Klein","year":"2022","unstructured":"Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989\u201398.","journal-title":"Neurology"},{"issue":"6","key":"1290_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108.","journal-title":"Epilepsia"},{"key":"1290_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106952","volume":"184","author":"B Abou-Khalil","year":"2022","unstructured":"Abou-Khalil B, Aboumatar S, Klein P, Krauss GL, Sperling MR, Rosenfeld WE. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;184:106952.","journal-title":"Epilepsy Res"},{"key":"1290_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110464","volume":"170","author":"M Toledo","year":"2025","unstructured":"Toledo M, Abraira L, L\u00f3pez-Maza S, Boy B, Campos-Fern\u00e1ndez D, Quintana M, et al. Steps towards seizure freedom with the use of cenobamate. Epilepsy Behav. 2025;170:110464.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1290_CR9","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s10072-025-08174-y","volume":"46","author":"CE Gjerulfsen","year":"2025","unstructured":"Gjerulfsen CE, Juhl S, Mieszczanek KM, Spanil L, Thygesen KS, Pavbro A, et al. Cenobamate as add-on treatment in ultra-refractory focal epilepsy: real-world results from the Danish Epilepsy Centre, Dianalund, Denmark. Neurol Sci. 2025;46(8):3875\u201384.","journal-title":"Neurol Sci"},{"issue":"3","key":"1290_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200460","volume":"15","author":"E Zengin","year":"2025","unstructured":"Zengin E, Erol F, Gil GA, Lado FA. Cenobamate monotherapy for focal epilepsy: a single-center retrospective study. Neurol Clin Pract. 2025;15(3):e200460.","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"1290_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/epi4.70021","volume":"10","author":"S Rheims","year":"2025","unstructured":"Rheims S, Steinhoff BJ, Hirsch E, Rosenow F, Biraben A, Thomas R, et al. Real-world effectiveness and tolerability of cenobamate in drug-resistant epilepsy: a retrospective analysis of the patients included into the early access programs (EAP) in Germany, France, and United Kingdom. Epilepsia Open. 2025;10(3):736\u201348.","journal-title":"Epilepsia Open"},{"issue":"17","key":"1290_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179339","volume":"22","author":"N Specchio","year":"2021","unstructured":"Specchio N, Pietrafusa N, Vigevano F. Is cenobamate the breakthrough we have been wishing for? Int J Mol Sci. 2021;22(17):9339.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1290_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","volume":"52","author":"W L\u00f6scher","year":"2011","unstructured":"L\u00f6scher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia. 2011;52(4):657\u201378.","journal-title":"Epilepsia"},{"issue":"3","key":"1290_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279\u201386.","journal-title":"JAMA Neurol"},{"issue":"6 Suppl.","key":"1290_CR15","doi-asserted-by":"publisher","first-page":"24S","DOI":"10.1177\/1535759720948437","volume":"20","author":"JA French","year":"2020","unstructured":"French JA. Do you believe in magic (bullets)? Epilepsy Curr. 2020;20(6 Suppl.):24S-S26.","journal-title":"Epilepsy Curr"},{"key":"1290_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107790","volume":"168","author":"M Janmohamed","year":"2020","unstructured":"Janmohamed M, Brodie MJ, Kwan P. Pharmacoresistance: epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology. 2020;168:107790.","journal-title":"Neuropharmacology"},{"issue":"Suppl. 1","key":"1290_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/epi.18306","volume":"66","author":"P Kwan","year":"2025","unstructured":"Kwan P, Brodie MJ. Do the third-generation antiseizure medications provide the \u201cmagic bullet\u201d for drug-resistant epilepsy? Focus on cenobamate. Epilepsia. 2025;66(Suppl. 1):1\u20133.","journal-title":"Epilepsia"},{"issue":"4","key":"1290_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ana.21064","volume":"62","author":"AL Luciano","year":"2007","unstructured":"Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol. 2007;62(4):375\u201381.","journal-title":"Ann Neurol"},{"issue":"4","key":"1290_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/ana.21166","volume":"62","author":"BC Callaghan","year":"2007","unstructured":"Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol. 2007;62(4):382\u20139.","journal-title":"Ann Neurol"},{"key":"1290_CR20","doi-asserted-by":"publisher","unstructured":"L\u00f6scher W, White HS, Klein P. The complexity and challenges of developing effective epilepsy therapies: lessons to be learned from comparing cenobamate, carisbamate and padsevonil. CNS Drugs. (2006). https:\/\/doi.org\/10.1007\/s40263-026-01284-x","DOI":"10.1007\/s40263-026-01284-x"},{"issue":"3","key":"1290_CR21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/epi.16832","volume":"62","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Sills GJ, White HS. The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ? Epilepsia. 2021;62(3):596\u2013614.","journal-title":"Epilepsia"},{"issue":"8","key":"1290_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","volume":"16","author":"JG Moffat","year":"2017","unstructured":"Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat Rev Drug Discov. 2017;16(8):531\u201343.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1290_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","volume":"21","author":"F Vincent","year":"2022","unstructured":"Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022;21(12):899\u2013914.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1290_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507\u201319.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1290_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41573-022-00552-x","volume":"21","author":"JW Scannell","year":"2022","unstructured":"Scannell JW, Bosley J, Hickman JA, Dawson GR, Truebel H, Ferreira GS, et al. Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nat Rev Drug Discov. 2022;21(12):915\u201331.","journal-title":"Nat Rev Drug Discov"},{"key":"1290_CR26","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.25813.1","volume":"9","author":"DC Swinney","year":"2020","unstructured":"Swinney DC, Lee JA. Recent advances in phenotypic drug discovery. F1000Research. 2020;9:944.","journal-title":"F1000Research"},{"issue":"8","key":"1290_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrd4336","volume":"13","author":"J Eder","year":"2014","unstructured":"Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov. 2014;13(8):577\u201387.","journal-title":"Nat Rev Drug Discov"},{"key":"1290_CR28","first-page":"1490","volume":"24","author":"R Gordon","year":"1998","unstructured":"Gordon R, Bernard P, Pack E, Lee K, Choi YM. Pharmacological profile of YKP10A: a novel antidepressant [abstract no. 583.9]. Soc Neurosci Abstr. 1998;24:1490.","journal-title":"Soc Neurosci Abstr."},{"issue":"7-8","key":"1290_CR29","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0278-5846(02)00298-1","volume":"26","author":"JD Amsterdam","year":"2002","unstructured":"Amsterdam JD, Brunswick DJ, Hundert M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A: a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(7\u20138):1333\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"1290_CR30","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/npp.2009.3","volume":"34","author":"S Hasan","year":"2009","unstructured":"Hasan S, Pradervand S, Ahnaou A, Drinkenburg W, Tafti M, Franken P. How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. Neuropsychopharmacology. 2009;34(7):1625\u201340.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1290_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/jpet.118.248120","volume":"366","author":"MG Baladi","year":"2018","unstructured":"Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367\u201376.","journal-title":"J Pharmacol Exp Ther"},{"key":"1290_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/0028-3908(73)90121-4","volume":"12","author":"M Kilian","year":"1973","unstructured":"Kilian M, Frey H-H. Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology. 1973;12:681\u201392.","journal-title":"Neuropharmacology"},{"key":"1290_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S0022-3565(24)38050-4","volume":"288","author":"W L\u00f6scher","year":"1999","unstructured":"L\u00f6scher W, Lehmann H, Teschendorf H-J, Traut M, Gross G. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999;288:984\u201392.","journal-title":"J Pharmacol Exp Ther"},{"key":"1290_CR34","first-page":"492","volume":"10","author":"DS Strac","year":"2016","unstructured":"Strac DS, Pivac N, Smolders IJ, Fogel WA, De Deurwaerdere P, Di Giovanni G. Monoaminergic mechanisms in epilepsy may offer innovative therapeutic opportunity for monoaminergic multi-target drugs. Front Neurosci. 2016;10:492\u2013492.","journal-title":"Front Neurosci"},{"issue":"1","key":"1290_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0014-2999(98)00580-9","volume":"358","author":"E Southam","year":"1998","unstructured":"Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol. 1998;358(1):19\u201324.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1290_CR36","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/j.1471-4159.1992.tb11001.x","volume":"59","author":"CS Biggs","year":"1992","unstructured":"Biggs CS, Pearce BR, Fowler LJ, Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem. 1992;59(5):1702\u20138.","journal-title":"J Neurochem"},{"key":"1290_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0014-2999(95)00831-4","volume":"299","author":"W L\u00f6scher","year":"1996","unstructured":"L\u00f6scher W, H\u00f6nack D. Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats. Eur J Pharmacol. 1996;299:61\u20137.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"1290_CR38","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/BF00969688","volume":"20","author":"MH Meshkibaf","year":"1995","unstructured":"Meshkibaf MH, Subhash MN, Lakshmana KM, Rao BS. Effect of chronic administration of phenytoin on regional monoamine levels in rat brain. Neurochem Res. 1995;20(7):773\u20138.","journal-title":"Neurochem Res"},{"issue":"2","key":"1290_CR39","first-page":"371","volume":"47","author":"S Kaneko","year":"1993","unstructured":"Kaneko S, Okada M, Hirano T, Kondo T, Otani K, Fukushima Y. Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread. Jpn J Psychiatry Neurol. 1993;47(2):371\u20133.","journal-title":"Jpn J Psychiatry Neurol"},{"issue":"1","key":"1290_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neulet.2005.07.049","volume":"390","author":"R Clinckers","year":"2005","unstructured":"Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine. Neurosci Lett. 2005;390(1):48\u201353.","journal-title":"Neurosci Lett"},{"issue":"6","key":"1290_CR41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.biopsych.2004.06.025","volume":"56","author":"LL Carpenter","year":"2004","unstructured":"Carpenter LL, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, et al. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biol Psychiatry. 2004;56(6):418\u201326.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"1290_CR42","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17434440.2018.1507732","volume":"15","author":"A Mertens","year":"2018","unstructured":"Mertens A, Raedt R, Gadeyne S, Carrette E, Boon P, Vonck K. Recent advances in devices for vagus nerve stimulation. Expert Rev Med Devices. 2018;15(8):527\u201339.","journal-title":"Expert Rev Med Devices"},{"key":"1290_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.790943","volume":"15","author":"A Berger","year":"2021","unstructured":"Berger A, Vespa S, Dricot L, Dumoulin M, Iachim E, Doguet P, et al. How is the norepinephrine system involved in the antiepileptic effects of vagus nerve stimulation? Front Neurosci. 2021;15:790943.","journal-title":"Front Neurosci"},{"issue":"3","key":"1290_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ner.13528","volume":"25","author":"CW Austelle","year":"2022","unstructured":"Austelle CW, O\u2019Leary GH, Thompson S, Gruber E, Kahn A, Manett AJ, et al. A comprehensive review of vagus nerve stimulation for depression. Neuromodulation. 2022;25(3):309\u201315.","journal-title":"Neuromodulation"},{"key":"1290_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2009.03.025","volume":"610","author":"W L\u00f6scher","year":"2009","unstructured":"L\u00f6scher W. Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur J Pharmacol. 2009;610:1\u201311.","journal-title":"Eur J Pharmacol"},{"key":"1290_CR46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.yebeh.2016.03.022","volume":"61","author":"AM Kanner","year":"2016","unstructured":"Kanner AM. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: a review of the evidence. Epilepsy Behav. 2016;61:282\u20136.","journal-title":"Epilepsy Behav"},{"key":"1290_CR47","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.1016\/S0040-4020(01)88100-X","volume":"42","author":"YM Choi","year":"1986","unstructured":"Choi YM, Kucharczyk N, Sofia RD. Metabolites of felbamate: synthesis of 2-(4-hydroxyphenyl)-1,3-propanediol dicarbamate, 2-phenyl-2-hydroxy-1,3-propanediol dicarbamate, and 2-phenyl-1,3-propanediol monocarbamate. Tetrahedron. 1986;42:6399\u2013404.","journal-title":"Tetrahedron"},{"issue":"20","key":"1290_CR48","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.wnl.0000334751.89859.7f","volume":"71","author":"E Faught","year":"2008","unstructured":"Faught E, Holmes GL, Rosenfeld WE, Novak G, Neto W, Greenspan A, et al. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology. 2008;71(20):1586\u201393.","journal-title":"Neurology"},{"issue":"3","key":"1290_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1528-1167.2009.02318.x","volume":"51","author":"MR Sperling","year":"2010","unstructured":"Sperling MR, Greenspan A, Cramer JA, Kwan P, K\u00e4lvi\u00e4inen R, Halford JJ, et al. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia. 2010;51(3):333\u201343.","journal-title":"Epilepsia"},{"issue":"4","key":"1290_CR50","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1528-1167.2010.02960.x","volume":"52","author":"JJ Halford","year":"2011","unstructured":"Halford JJ, Ben Menachem E, Kwan P, Ness S, Schmitt J, Eerdekens M, et al. A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia. 2011;52(4):816\u201325.","journal-title":"Epilepsia"},{"issue":"1","key":"1290_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14728214.2022.2059464","volume":"27","author":"AW Pong","year":"2022","unstructured":"Pong AW, Ross J, Tyrlikova I, Giermek AJ, Kohli MP, Khan YA, et al. Epilepsy: expert opinion on emerging drugs in phase 2\/3 clinical trials. Expert Opin Emerg Drugs. 2022;27(1):75\u201390.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1290_CR52","doi-asserted-by":"publisher","first-page":"175628642311910","DOI":"10.1177\/17562864231191000","volume":"16","author":"GJ Sills","year":"2023","unstructured":"Sills GJ. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies. Ther Adv Neurol Disord. 2023;16:17562864231191000.","journal-title":"Ther Adv Neurol Disord"},{"issue":"Suppl. 1","key":"1290_CR53","first-page":"P9","volume":"104","author":"V Vashi","year":"2025","unstructured":"Vashi V, Vossler D. Carisbamate treatment of adult and pediatric patients with Lennox\u2013Gastaut syndrome: a phase I pharmacokinetic dose-escalation study. Neurology. 2025;104(Suppl. 1):P9-9.007.","journal-title":"Neurology"},{"issue":"4","key":"1290_CR54","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/dmd.106.011940","volume":"35","author":"GS Mannens","year":"2007","unstructured":"Mannens GS, Hendrickx J, Janssen CG, Chien S, Van Hoof B, Verhaeghe T, et al. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab Dispos. 2007;35(4):554\u201365.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1290_CR55","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.3390\/molecules20045528","volume":"20","author":"CX Wei","year":"2015","unstructured":"Wei CX, Bian M, Gong GH. Tetrazolium compounds: synthesis and applications in medicine. Molecules. 2015;20(4):5528\u201353.","journal-title":"Molecules"},{"key":"1290_CR56","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1055\/s-0037-1611863","volume":"51","author":"R Mittal","year":"2019","unstructured":"Mittal R, Awasthi SK. Recent advances in the synthesis of 5-substituted 1H-tetrazoles: a complete survey (2013\u20132018). Synthesis. 2019;51:3765\u201383.","journal-title":"Synthesis"},{"key":"1290_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116870","volume":"279","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Li M, Apostolopoulos V, Matsoukas J, Wolf WM, Blaskovich MAT, et al. Tetrazoles: a multi-potent motif in drug design. Eur J Med Chem. 2024;279:116870.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"1290_CR58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4155\/fmc-2019-0288","volume":"12","author":"Y Zou","year":"2020","unstructured":"Zou Y, Liu L, Liu J, Liu G. Bioisosteres in drug discovery: focus on tetrazole. Future Med Chem. 2020;12(2):91\u20133.","journal-title":"Future Med Chem"},{"key":"1290_CR59","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1070\/RCR4864","volume":"88","author":"EA Popova","year":"2019","unstructured":"Popova EA, Trifonov RE, Ostrovskii VA. Tetrazoles for biomedicine. Russ Chem Rev. 2019;88:644\u201376.","journal-title":"Russ Chem Rev"},{"key":"1290_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0041-008X(64)90018-3","volume":"6","author":"CL Mitchell","year":"1964","unstructured":"Mitchell CL. The anticonvulsant activity of some tetrazole derivatives. Toxicol Appl Pharmacol. 1964;6:23\u20138.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1290_CR61","volume":"Chapter 1","author":"AK Mehta","year":"2001","unstructured":"Mehta AK, Ticku MK. Characterization of the picrotoxin site of GABAA receptors. Curr Protoc Pharmacol. 2001;Chapter 1:Unit 1.18.","journal-title":"Curr Protoc Pharmacol"},{"issue":"10","key":"1290_CR62","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1021\/acs.jmedchem.4c00652","volume":"67","author":"Q Guan","year":"2024","unstructured":"Guan Q, Xing S, Wang L, Zhu J, Guo C, Xu C, et al. Triazoles in medicinal chemistry: physicochemical properties, bioisosterism, and application. J Med Chem. 2024;67(10):7788\u2013824.","journal-title":"J Med Chem"},{"key":"1290_CR63","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ejmech.2016.01.009","volume":"109","author":"A Ayati","year":"2016","unstructured":"Ayati A, Emami S, Foroumadi A. The importance of triazole scaffold in the development of anticonvulsant agents. Eur J Med Chem. 2016;109:380\u201392.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1290_CR64","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14756366.2017.1423068","volume":"33","author":"MX Song","year":"2018","unstructured":"Song MX, Deng XQ. Recent developments on triazole nucleus in anticonvulsant compounds: a review. J Enzyme Inhib Med Chem. 2018;33(1):453\u201378.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"6","key":"1290_CR65","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1586\/ern.10.51","volume":"10","author":"CD Ferrie","year":"2010","unstructured":"Ferrie CD. Rufinamide: a new antiepileptic drug treatment for Lennox\u2013Gastaut syndrome. Expert Rev Neurother. 2010;10(6):851\u201360.","journal-title":"Expert Rev Neurother"},{"key":"1290_CR66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0920-1211(94)90012-4","volume":"17","author":"W L\u00f6scher","year":"1994","unstructured":"L\u00f6scher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 1994;17:95\u2013134.","journal-title":"Epilepsy Res"},{"key":"1290_CR67","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ddr.430190404","volume":"19","author":"A Wauquier","year":"1990","unstructured":"Wauquier A, Fransen J, Melis W, Ashton D, Gillardin J-M, Lewi P, et al. Loreclezole (R 72063): an anticonvulsant chemically unrelated to prototype anticonvulsants. Drug Dev Res. 1990;19:375\u201392.","journal-title":"Drug Dev Res"},{"issue":"8","key":"1290_CR68","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.seizure.2013.04.015","volume":"22","author":"LJ Greenfield Jr","year":"2013","unstructured":"Greenfield LJ Jr. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure. 2013;22(8):589\u2013600.","journal-title":"Seizure"},{"issue":"1","key":"1290_CR69","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0920-1211(91)90047-J","volume":"9","author":"T Rentmeester","year":"1991","unstructured":"Rentmeester T, Janssen A, Hulsman J, Scholtes F, van der Kleij B, Overweg J, et al. A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures. Epilepsy Res. 1991;9(1):59\u201364.","journal-title":"Epilepsy Res"},{"key":"1290_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114780","volume":"244","author":"X Simeone","year":"2022","unstructured":"Simeone X, Ernst M, Seidel T, Heider J, Enz D, Monticelli S, et al. Novel alpha6 preferring GABA-A receptor ligands based on loreclezole. Eur J Med Chem. 2022;244:114780.","journal-title":"Eur J Med Chem"},{"key":"1290_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108808","volume":"268","author":"M Bialer","year":"2025","unstructured":"Bialer M, Perucca E. From barbiturates to ganaxolone: the importance of chirality in drug development and in understanding the actions of old and new antiseizure medications. Pharmacol Ther. 2025;268:108808.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1290_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","volume":"83","author":"M Bialer","year":"2009","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83(1):1\u201343.","journal-title":"Epilepsy Res"},{"issue":"8","key":"1290_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18920","volume":"9","author":"SM Melnick","year":"2023","unstructured":"Melnick SM, Shin Y, Glenn KJ. Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents. Heliyon. 2023;9(8):e18920.","journal-title":"Heliyon"},{"issue":"3","key":"1290_CR74","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40263-024-01155-3","volume":"39","author":"E Perucca","year":"2025","unstructured":"Perucca E, Taglialatela M. Targeting Kv7 potassium channels for epilepsy. CNS Drugs. 2025;39(3):263\u201388.","journal-title":"CNS Drugs"},{"issue":"4","key":"1290_CR75","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/epi.12950","volume":"56","author":"M Treven","year":"2015","unstructured":"Treven M, Koenig X, Assadpour E, Gantumur E, Meyer C, Hilber K, et al. The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors. Epilepsia. 2015;56(4):647\u201357.","journal-title":"Epilepsia"},{"issue":"1","key":"1290_CR76","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","volume":"103","author":"M Bialer","year":"2013","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013;103(1):2\u201330.","journal-title":"Epilepsy Res"},{"key":"1290_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109923","volume":"158","author":"W L\u00f6scher","year":"2024","unstructured":"L\u00f6scher W. Mammalian models of status epilepticus: their value and limitations. Epilepsy Behav. 2024;158:109923.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"1290_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091233","volume":"12","author":"W L\u00f6scher","year":"2023","unstructured":"L\u00f6scher W, White HS. Animal models of drug-resistant epilepsy as tools for deciphering the cellular and molecular mechanisms of pharmacoresistance and discovering more effective treatments. Cells. 2023;12(9):1233.","journal-title":"Cells"},{"issue":"9","key":"1290_CR79","doi-asserted-by":"publisher","first-page":"18284","DOI":"10.3390\/ijms140918284","volume":"4","author":"DS Reddy","year":"2013","unstructured":"Reddy DS, Kuruba R. Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. Int J Mol Sci. 2013;4(9):18284\u2013318.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1290_CR80","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0165-0173(87)90002-6","volume":"434","author":"WA Turski","year":"1987","unstructured":"Turski WA, Cavalheiro EA, Coimbra C, da Penha BM, Ikonomidou-Turski C, Turski L. Only certain antiepileptic drugs prevent seizures induced by pilocarpine. Brain Res. 1987;434(3):281\u2013305.","journal-title":"Brain Res"},{"key":"1290_CR81","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","volume":"232","author":"W L\u00f6scher","year":"1993","unstructured":"L\u00f6scher W, H\u00f6nack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993;232:147\u201358.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"1290_CR82","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","volume":"30","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs. 2016;30(11):1055\u201377.","journal-title":"CNS Drugs"},{"key":"1290_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107811","volume":"166","author":"KS Wilcox","year":"2020","unstructured":"Wilcox KS, West PJ, Metcalf CS. The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology. 2020;166:107811.","journal-title":"Neuropharmacology"},{"issue":"4","key":"1290_CR84","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/epi4.12997","volume":"9","author":"H Zhang","year":"2024","unstructured":"Zhang H, Ou Z, Zhang E, Liu W, Hao N, Chen Y, et al. Efficacy and safety of add-on antiseizure medications for focal epilepsy: a network meta-analysis. Epilepsia Open. 2024;9(4):1550\u201364.","journal-title":"Epilepsia Open"},{"key":"1290_CR85","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","volume":"20","author":"W L\u00f6scher","year":"2011","unstructured":"L\u00f6scher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20:359\u201368.","journal-title":"Seizure"},{"key":"1290_CR86","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","volume":"47","author":"ME Barton","year":"2001","unstructured":"Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47:217\u201328.","journal-title":"Epilepsy Res"},{"key":"1290_CR87","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/epi.16718","volume":"61","author":"M Guignet","year":"2020","unstructured":"Guignet M, Campbell A, White HS. Cenobamate (Xcopri\u00ae): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia. 2020;61:2329\u201339.","journal-title":"Epilepsia"},{"key":"1290_CR88","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0920-1211(88)90054-X","volume":"2","author":"W L\u00f6scher","year":"1988","unstructured":"L\u00f6scher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988;2:145\u201381.","journal-title":"Epilepsy Res"},{"key":"1290_CR89","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","volume":"126","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016;126:157\u201384.","journal-title":"Epilepsy Res"},{"key":"1290_CR90","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","volume":"855","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175\u201382.","journal-title":"Eur J Pharmacol"},{"key":"1290_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173117","volume":"79","author":"R Sharma","year":"2020","unstructured":"Sharma R, Nakamura M, Neupane C, Jeon BH, Shin H, Melnick SM, et al. Positive allosteric modulation of GABA(A) receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;79:173117.","journal-title":"Eur J Pharmacol"},{"key":"1290_CR92","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.seizure.2025.11.010","volume":"134","author":"R Sankar","year":"2026","unstructured":"Sankar R, Ferrari L, Kamin M. Exploration of the mechanism of action of cenobamate. Seizure. 2026;134:79\u201385.","journal-title":"Seizure"},{"issue":"10","key":"1290_CR93","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00424-024-02980-7","volume":"476","author":"P M\u00fcller","year":"2024","unstructured":"M\u00fcller P, Draguhn A, Egorov AV. Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers. Pflugers Arch. 2024;476(10):1445\u201373.","journal-title":"Pflugers Arch"},{"issue":"1","key":"1290_CR94","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1535759720973978","volume":"21","author":"ER Wengert","year":"2021","unstructured":"Wengert ER, Patel MK. The role of the persistent sodium current in epilepsy. Epilepsy Curr. 2021;21(1):40\u20137.","journal-title":"Epilepsy Curr"},{"key":"1290_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fncir.2014.00003","volume":"8","author":"V Lee","year":"2014","unstructured":"Lee V, Maguire J. The impact of tonic GABAA receptor-mediated inhibition on neuronal excitability varies across brain region and cell type. Front Neural Circuits. 2014;8:3.","journal-title":"Front Neural Circuits"},{"issue":"Suppl.","key":"1290_CR96","doi-asserted-by":"publisher","first-page":"P1.5-033","DOI":"10.1212\/WNL.92.15_supplement.P1.5-033","volume":"92","author":"R Sharma","year":"2019","unstructured":"Sharma R, Song WS, Nakamura M, Neupane C, Shin H, Melnick SM, et al. Effects of cenobamate on GABA-A receptor modulation. Neurology. 2019;92(Suppl.):P1.5-033.","journal-title":"Neurology"},{"key":"1290_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107966","volume":"168","author":"GJ Sills","year":"2020","unstructured":"Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966.","journal-title":"Neuropharmacology"},{"key":"1290_CR98","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.seizure.2022.03.024","volume":"98","author":"YF Bai","year":"2022","unstructured":"Bai YF, Zeng C, Jia M, Xiao B. Molecular mechanisms of topiramate and its clinical value in epilepsy. Seizure. 2022;98:51\u20136.","journal-title":"Seizure"},{"issue":"3","key":"1290_CR99","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","volume":"53","author":"MJ Gunthorpe","year":"2012","unstructured":"Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012;53(3):412\u201324.","journal-title":"Epilepsia"},{"issue":"1","key":"1290_CR100","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0028-3908(00)00112-X","volume":"40","author":"MA Rogawski","year":"2001","unstructured":"Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology. 2001;40(1):28\u201335.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1290_CR101","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1021\/jm00105a016","volume":"34","author":"PL Ornstein","year":"1991","unstructured":"Ornstein PL, Schoepp DD, Arnold MB, Leander JD, Lodge D, Paschal JW, et al. 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids: potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action. J Med Chem. 1991;34(1):90\u20137.","journal-title":"J Med Chem"},{"issue":"15","key":"1290_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157029","volume":"26","author":"L Bettio","year":"2025","unstructured":"Bettio L, Bankar G, Dub\u00e9 CM, Nelkenbrecher K, Filipovic M, Singh S, et al. The pharmacokinetic and pharmacodynamic relationship of clinically used antiseizure medications in the maximal electroshock seizure model in rodents. Int J Mol Sci. 2025;26(15):7029.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1290_CR103","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13318-023-00862-4","volume":"49","author":"J Palamanda","year":"2024","unstructured":"Palamanda J, Glenn KJ, Melnick SM. Distribution, metabolism, and excretion of cenobamate in adult, fetal, neonatal, and lactating rats. Eur J Drug Metab Pharmacokinet. 2024;49(1):7\u201321.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"Suppl.","key":"1290_CR104","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.1377","volume":"96","author":"SA Greene","year":"2021","unstructured":"Greene SA, Kamin M. Cenobamate trough plasma concentrations in patients with uncontrolled focal seizures achieving 50% and 100% seizure reduction in two randomized clinical studies. Neurology. 2021;96(Suppl.):1377.","journal-title":"Neurology"},{"issue":"10","key":"1290_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13102757","volume":"13","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff BJ, Georgiou D, Dietmann D, Intravooth T. Cenobamate plasma levels in patients with epilepsy: correlation with efficacy and tolerability? J Clin Med. 2024;13(10):2757.","journal-title":"J Clin Med"},{"issue":"4","key":"1290_CR106","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1528-1167.2006.00504.x","volume":"47","author":"B Rambeck","year":"2006","unstructured":"Rambeck B, J\u00fcrgens UH, May TW, Pannek HW, Behne F, Ebner A, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia. 2006;47(4):681\u201394.","journal-title":"Epilepsia"},{"issue":"4","key":"1290_CR107","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/cpdd.769","volume":"9","author":"L Vernillet","year":"2020","unstructured":"Vernillet L, Greene SA, Kamin M. Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects. Clin Pharmacol Drug Dev. 2020;9(4):428\u201343.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"1290_CR108","doi-asserted-by":"publisher","first-page":"e559","DOI":"10.1212\/WNL.0000000000007894","volume":"93","author":"DGA Kasteleijn-Nolst Trenit\u00e9","year":"2019","unstructured":"Kasteleijn-Nolst Trenit\u00e9 DGA, DiVentura BD, Pollard JR, Krauss GL, Mizne S, French JA. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089). Neurology. 2019;93(6):e559\u201367.","journal-title":"Neurology"},{"issue":"2","key":"1290_CR109","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/WCO.0000000000001144","volume":"36","author":"AW Pong","year":"2023","unstructured":"Pong AW, Xu KJ, Klein P. Recent advances in pharmacotherapy for epilepsy. Curr Opin Neurol. 2023;36(2):77\u201385.","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"1290_CR110","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/epi4.12830","volume":"8","author":"B Schmitz","year":"2023","unstructured":"Schmitz B, Lattanzi S, Vonck K, K\u00e4lvi\u00e4inen R, Nashef L, Ben Menachem E. Cenobamate in refractory epilepsy: overview of treatment options and practical considerations. Epilepsia Open. 2023;8(4):1241\u201355.","journal-title":"Epilepsia Open"},{"issue":"1","key":"1290_CR111","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrd2997","volume":"9","author":"M Bialer","year":"2010","unstructured":"Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68\u201382.","journal-title":"Nat Rev Drug Discov"},{"key":"1290_CR112","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","volume":"23","author":"P Klein","year":"2024","unstructured":"Klein P, Kaminski RM, Koepp M, L\u00f6scher W. New epilepsy therapies in development. Nat Rev Drug Discov. 2024;23:682\u2013708.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1290_CR113","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1527-3458.2007.00004.x","volume":"13","author":"T De Smedt","year":"2007","unstructured":"De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007;13(1):43\u201356.","journal-title":"CNS Drug Rev"},{"key":"1290_CR114","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/j.1528-1157.1997.tb01212.x","volume":"38","author":"P Wlaz","year":"1997","unstructured":"Wlaz P, L\u00f6scher W. Anticonvulsant activity of felbamate in amygdala kindling model of temporal lobe epilepsy in rat. Epilepsia. 1997;38:1167\u201372.","journal-title":"Epilepsia"},{"key":"1290_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176222","volume":"962","author":"A Leo","year":"2024","unstructured":"Leo A, Bosco F, Guarnieri L, De Sarro C, Rania V, Gallelli L, et al. Cenobamate enhances the anticonvulsant effect of other antiseizure medications in the DBA\/2 mouse model of reflex epilepsy. Eur J Pharmacol. 2024;962:176222.","journal-title":"Eur J Pharmacol"},{"key":"1290_CR116","doi-asserted-by":"publisher","first-page":"1223074","DOI":"10.3389\/fneur.2023.1223074","volume":"14","author":"F Bosco","year":"2023","unstructured":"Bosco F, Guarnieri L, Leo A, Tallarico M, Gallelli L, Rania V, et al. Audiogenic epileptic DBA\/2 mice strain as a model of genetic reflex seizures and SUDEP. Front Neurol. 2023;14:1223074.","journal-title":"Front Neurol"},{"key":"1290_CR117","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1124\/jpet.119.261222","volume":"372","author":"K Leclercq","year":"2020","unstructured":"Leclercq K, Matagne A, Provins L, Klitgaard H, Kaminski RM. Pharmacological profile of the antiepileptic drug candidate padsevonil: characterization in rodent seizure and epilepsy models. J Pharmacol Exp Ther. 2020;372:11\u201320.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2-3","key":"1290_CR118","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.eplepsyres.2007.03.004","volume":"4","author":"T St\u00f6hr","year":"2007","unstructured":"St\u00f6hr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007;4(2\u20133):147\u201354.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1290_CR119","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1528-1167.2007.01278.x","volume":"49","author":"J Francois","year":"2008","unstructured":"Francois J, Boehrer A, Nehlig A. Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia. 2008;49(3):393\u20139.","journal-title":"Epilepsia"},{"key":"1290_CR120","unstructured":"Klein BD, Smith MD, White HS. The novel neuromodulator carisbamate delays the acquisition of rat amygdala kindling and maintains acute antiepileptic activity when evaluated in post-kindled rats. American Epilepsy Society (AES) Annual Meeting; 2007; Philadelpha (PA): abstract number 3.322. https:\/\/aesnet.org\/abstractslisting\/the-novel-neuromodulator-carisbamate-delays-the-acquisition-of-rat-amygdala-kindling-and-maintains-acute-antiepileptic-activity-when-evaluated-in-post-kindled-rats-. Accessed 29 Mar 2026."},{"issue":"1","key":"1290_CR121","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1528-1157.1986.tb03497.x","volume":"27","author":"EA Swinyard","year":"1986","unstructured":"Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia. 1986;27(1):27\u201334.","journal-title":"Epilepsia"},{"issue":"3","key":"1290_CR122","first-page":"335","volume":"79","author":"RD Sofia","year":"1993","unstructured":"Sofia RD, Gordon R, Gels M, Diamantis W. Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. Res Commun Chem Pathol Pharmacol. 1993;79(3):335\u201341.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"1290_CR123","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0920-1211(97)01021-8","volume":"27","author":"HH Frey","year":"1997","unstructured":"Frey HH, Bartels I. Felbamate and meprobamate: a comparison of their anticonvulsant properties. Epilepsy Res. 1997;27:151\u201364.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1290_CR124","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1528-1167.2011.03364.x","volume":"53","author":"CH Large","year":"2012","unstructured":"Large CH, Sokal DM, Nehlig A, Gunthorpe MJ, Sankar R, Crean CS, et al. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia. 2012;53(3):425\u201336.","journal-title":"Epilepsia"},{"issue":"3","key":"1290_CR125","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2005.11.001","volume":"68","author":"MG Vartanian","year":"2006","unstructured":"Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 2006;68(3):189\u2013205.","journal-title":"Epilepsy Res"},{"issue":"4","key":"1290_CR126","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00213-009-1682-5","volume":"207","author":"GA Higgins","year":"2010","unstructured":"Higgins GA, Breysse N, Undzys E, Derksen DR, Jeffrey M, Scott BW, et al. Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology. 2010;207(4):513\u201327.","journal-title":"Psychopharmacology"},{"issue":"2-3","key":"1290_CR127","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eplepsyres.2010.09.002","volume":"92","author":"NM Rowley","year":"2010","unstructured":"Rowley NM, White HS. Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models. Epilepsy Res. 2010;92(2\u20133):163\u20139.","journal-title":"Epilepsy Res"},{"issue":"8","key":"1290_CR128","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/bjp.2008.198","volume":"154","author":"A Matagne","year":"2008","unstructured":"Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154(8):1662\u201371.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"1290_CR129","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/sj.bjp.0706791","volume":"148","author":"AA Gurbanova","year":"2006","unstructured":"Gurbanova AA, Aker R, Berkman K, Onat FY, van Rijn CM, Van Luijtelaar G. Effect of systemic and intracortical administration of phenytoin in two genetic models of absence epilepsy. Br J Pharmacol. 2006;148(8):1076\u201382.","journal-title":"Br J Pharmacol"},{"key":"1290_CR130","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0920-1211(97)00031-4","volume":"28","author":"NO Dalby","year":"1997","unstructured":"Dalby NO, Nielsen EB. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res. 1997;28:63\u201372.","journal-title":"Epilepsy Res"},{"key":"1290_CR131","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eplepsyres.2018.06.009","volume":"145","author":"N Nirwan","year":"2018","unstructured":"Nirwan N, Siraj F, Vohora D. Inverted-U response of lacosamide on pilocarpine-induced status epilepticus and oxidative stress in C57BL\/6 mice is independent of hippocampal collapsin response mediator protein-2. Epilepsy Res. 2018;145:93\u2013101.","journal-title":"Epilepsy Res"},{"key":"1290_CR132","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5152\/ArchEpilepsy.2022.222653","volume":"28","author":"O S\u00fcmb\u00fcl","year":"2022","unstructured":"S\u00fcmb\u00fcl O, K\u00f6roglu R, Ayg\u00fcn H. Lacosamide increases absence seizures and anxiety-like behavior in WAG\/Rij rat model. Arch Epilepsy. 2022;28:142\u20138.","journal-title":"Arch Epilepsy"},{"issue":"2-3","key":"1290_CR133","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.eplepsyres.2009.11.010","volume":"88","author":"W Zgrajka","year":"2010","unstructured":"Zgrajka W, Nieoczym D, Czuczwar M, Kis\u015b J, Brzana W, Wla\u017a P, et al. Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. Epilepsy Res. 2010;88(2\u20133):269\u201374.","journal-title":"Epilepsy Res"},{"issue":"Suppl. 1","key":"1290_CR134","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","volume":"41","author":"RP Shank","year":"2000","unstructured":"Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl. 1):S3-9.","journal-title":"Epilepsia"},{"issue":"1","key":"1290_CR135","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1046\/j.1528-1157.2003.32902.x","volume":"44","author":"MA Rigoulot","year":"2003","unstructured":"Rigoulot MA, Boehrer A, Nehlig A. Effects of topiramate in two models of genetically determined generalized epilepsy, the GAERS and the Audiogenic Wistar AS. Epilepsia. 2003;44(1):14\u20139.","journal-title":"Epilepsia"},{"issue":"1-2","key":"1290_CR136","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neuropharm.2011.04.018","volume":"61","author":"J Francois","year":"2011","unstructured":"Francois J, Germe K, Ferrandon A, Koning E, Nehlig A. Carisbamate has powerful disease-modifying effects in the lithium-pilocarpine model of temporal lobe epilepsy. Neuropharmacology. 2011;61(1\u20132):313\u201328.","journal-title":"Neuropharmacology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01290-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01290-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01290-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:03:11Z","timestamp":1782385391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01290-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":136,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01290-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yong Moon Choi founded SK Biopharmaceuticals (Fairfield, NJ, USA and Daeduk\/Seoul,\u00a0South\u00a0Korea) in 1993, was Executive Vice President of the company during the development of cenobamate (till 2006), and, since 2008, is the CEO of Bio-Pharm Solutions (Seoul, South Korea). H. Steve White directed the NINDS ETSP at the University of Utah during the development of cenobamate. He has received grant funding from Neurelis and consultant fees from BioPharm Solutions and JAZZ Pharmaceuticals, and speaker honoraria from SK Life Sciences, Takeda, and UCB Pharma. He is also a co-founder of NeuroAdjuvants, Inc., Salt Lake City, UT, USA. Pavel Klein took part in all three pivotal clinical trials of cenobamate, co-authored two of the three foundational manuscripts (Krauss et al., 2020; Sperling et al., 2020), with access to complete study reports for both trials, and lead-authored the open-label extension manuscript of the most important pivotal trial (Klein et al., 2022), in addition to co-authoring a host of secondary cenobamate efficacy and safety manuscripts derived from the pivotal trial data. He has served as a consultant, advisory board member, or speaker (2020\u201325) for Abbott,\u00a0Angelini Pharma, Aquestive Therapeutics, Arvelle Therapeutics,\u00a0Aucta Pharmaceuticals, Dr. Reddy\u2019s, Eisai, GRIN Therapeutics, Jazz Pharmaceuticals, Longboard Pharmaceuticals, Neurelis, Inc., Neurona Therapeutics, Paladin Pharma, SK Life Science, Sunovion, UCB Pharma, UNEEG, UniQure, and Xenon Pharma, is a member of the Data and Safety Monitoring Board for Neurona Therapeutics, and is a member of the Medical Advisory Board of Stratus and the Scientific Advisory Boards of OB Pharma and of NEUmirna, is the CEO of PrevEp, Inc. (Bethesda, MD, USA),\u00a0and has received research support from CURE\/Department of Defense and from the NIH\/SBIR. Wolfgang L\u00f6scher is a member of the External Consultant Board of the NINDS ETSP program. He is a co-founder and CSO of PrevEp, Inc. (Bethesda, MD, USA). He has received in the past 5 years consultancy fees from Lundbeck, Angelini, Clexio, Selene, Axonis, SynapCell, Sintetica, ND Capital, Atlas Venture, Cogent Biosolutions, Ovid, Idorsia, and Addex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No primary data were collected for this study. The original data extraction is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"WL: conceptualization (lead); investigation (equal); visualization (lead); writing (original draft preparation [lead]); writing (review and editing [equal]); YMC: writing (review and editing [equal]); investigation (equal). HSW: writing (review and editing [equal]); investigation (equal). PK: writing (review and editing [equal]); investigation (equal). All authors reviewed and approved the final paper.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}